NCT00753064 is a Phase 3 clinical trial of Antiscorpion venom serum(AScVS). in Scorpion Envenomation, sponsored by Haffkine Bio-Pharmaceutical Corporation Ltd..

Who is sponsoring NCT00753064?

NCT00753064 is sponsored by Haffkine Bio-Pharmaceutical Corporation Ltd..

What drugs are being tested in NCT00753064?

Interventions in NCT00753064: Antiscorpion venom serum(AScVS)., T.Prazosin, AScVS + Prazosin.

What condition does NCT00753064 study?

NCT00753064 studies Scorpion Envenomation.

Is NCT00753064 still recruiting?

NCT00753064 is currently completed. Last updated 15 September 2008.

Last reviewed 2008-09-15 · How we verify

NCT00753064

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparative Study of Efficacy of Antiscorpion Venom Serum(AScVS)vs Prazosin in the Management of Severe Scorpion(Mesobuthus Tamulus Concanesis Pocock)Envenomation and Evaluation of Effects of the Combination of AScVS + Prazosin Therapy.

Completed Phase 3 Last updated 15 September 2008

What this trial tests

Phase 3 trial testing Antiscorpion venom serum(AScVS). in Scorpion Envenomation in 81 participants. Completed in 1 December 2007.

Timeline

1 September 2006

Primary endpoint
1 December 2007

1 December 2007

Quick facts

Lead sponsor	Haffkine Bio-Pharmaceutical Corporation Ltd.
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	81
Start date	1 September 2006
Primary completion	1 December 2007
Estimated completion	1 December 2007
Sites	5 locations across India

Drugs / interventions tested

Antiscorpion venom serum(AScVS). — full drug profile →
T.Prazosin — full drug profile →
AScVS + Prazosin — full drug profile →

Conditions studied

Scorpion Envenomation — all drugs for Scorpion Envenomation →

Sponsor

Haffkine Bio-Pharmaceutical Corporation Ltd. — full company profile →

Who can join

Adults 12 to 65, any sex, with Scorpion Envenomation. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Superiority of AScVS and AScVS+Prazosin was confirmed over use of Prazosin alone.
Time frame: 1year 4 months.

Sponsor's own description

The data available for the efficacy of AScVS and prazosin is generated through different trials done in different clinical setting. Hence it was felt worthwhile to confirm the documented efficacy of AScVS and prazosin in terms of time taken for clinical recovery in a clinical trial. Along with this, effects of both the therapies on various biochemical parameters will be recorded and compared with. It was also felt necessary to study the effect of combination on the clinical outcome.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00753064 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Haffkine Bio-Pharmaceutical Corporation Ltd.
Last refreshed: 15 September 2008

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00753064.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing